About Adacel Vaccine
Adacel vaccine is the first booster to address pertussis protection across a wide range of ages (11 through 64 years) and the first and only booster licensed for adults in the United States. It was licensed by the U.S. Food and Drug Administration (FDA) on June 10, 2005. Adacel vaccine is administered as a single, 0.5mL dose by intramuscular injection. It is similar to DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), a diphtheria, tetanus, and pertussis vaccine used to protect infants and young children because it is also based on sanofi pasteur's 5-antigen pertussis vaccine. In clinical studies, DAPTACEL vaccine has been shown to provide 85 percent efficacy against severe pertussis (cough lasting 21 days or longer) and 78 percent efficacy against all severities of pertussis.
Important Safety Information
There are risks associated with all vaccines. The most common
injection site adverse events include pain, erythema, and swelling.
The most common systemic adverse events include headache, body
ache, tiredness, and fever. Adacel vaccine is contraindicated in
persons with known systemic hypersensitivity to any component of
the vaccine or a life-threatening reaction after previous
administration of the vaccine or a vaccine containing the same
substances. Because of uncertainty as to which component of the
vaccine may be responsible, no further vaccination with the
diphtheria, tetanus, or pertussis components found in Adacel
vaccine should be carried out. Because any intramuscular injection
can cause injection site hematoma, Adacel vaccine should not be
given to p